Agoracom Blog Home

Posts Tagged ‘small cap’

VIDEO – ORTHO Regenerative Technologies $ORTH.ca $ORTIF Is Preparing for The Big League, Appointing Patrick O’Donnell to Help Bring its Proprietary Surgery Tech to NASDAQ

Posted by AGORACOM-JC at 4:17 PM on Monday, March 1st, 2021
Ortho

Last week we introduced you to ORTHO Regenerative Technologies, a cutting-edge med tech firm that uses its proprietary RESTORE technology platform to dramatically improve the success rate of orthopedic and sports medicine surgeries.

  • In layman’s terms, that means company has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.

Now the firm has appointed Patrick O’Donnell to its board of directors.

  • O’Donnell comes with significant company-building experience
  • He will prove crucial in putting this healthcare pioneer on-track for a NASDAQ listing

Claude LeDuc, Ortho’s CEO, breaks down the appointment:

Draganfly $DFLY.ca $DFLYF CEO Cameron Chell Will Speak at Canaccord Genuity Inaugural Global Sustainability Event $FLT.ca $UAVS $ALPP

Posted by AGORACOM-JC at 9:37 AM on Thursday, February 25th, 2021
  • Cameron Chell, will speak on the Sustainability/Rethinking Impact 2021 panel hosted by Canaccord Genuity.
  • The virtual event takes place on March 4, 2021 at 10AM PST/1PM EST.

Los Angeles, CA, Feb. 25, 2021 — Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer‎, announced today that the CEO of the Company, Cameron Chell, will speak on the Sustainability/Rethinking Impact 2021 panel hosted by Canaccord Genuity.

The virtual event takes place on March 4, 2021 at 10AM PST/1PM EST. Cameron Chell will join a panel to discuss: Rethinking Autonomy and the Drone Economy moderated by Ken Herbert, Managing Director, Canaccord Genuity Equity Research. The panel will focus on drones and their disruptive potential in the package delivery and logistics markets,

“I am honored to be part of Canaccord’s inaugural Global Sustainability Event,” said Cameron Chell, CEO of Draganfly. “Canaccord has put together aligned research across multiple geographies and I look forward to discussing how Draganfly has been a disruptive force in the health tech and drone delivery markets.”

To learn more about the event visit: https://www.canaccordgenuity.com/capital-markets/about-us/events/ .

Read More: https://agoracom.com/ir/Draganfly/forums/discussion/topics/756067-draganfly-ceo-cameron-chell-will-speak-at-canaccord-genuity-inaugural-global-sustainability-event/messages/2305347#message

Empower Clinics $CBDT.ca $EPWCF Announces Locations of First Three Integrated Health Centres in Ontario. Each Location Anticipated to Generate Approximately $3,000,000 In Revenue. Further Locations to Be Announced $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 8:01 AM on Thursday, February 25th, 2021

Launch Confirms Empower Stated Strategy To Execute National Clinic Expansion Following Canadian Clinics Acquisition And Partnership Announcements in 2021

  • Announce the launch of its first three integrated health centres in Ontario, Canada with each location expected to generate $2,560,000 – $3,600,000 in annual revenue.
  • Advanced discussions are currently underway on multiple additional locations as the Company begins the rollout of its national clinic expansion strategy.

VANCOUVER, BC / February 25, 2021 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving patients through medical centres, telemedicine platforms, operating a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens, is pleased to announce the launch of its first three integrated health centres in Ontario, Canada with each location expected to generate $2,560,000 – $3,600,000 in annual revenue. Advanced discussions are currently underway on multiple additional locations as the Company begins the rollout of its national clinic expansion strategy.

THREE ONTARIO LOCATIONS AND TWELVE PHYSICIANS COMMITTED TO OPEN

The locations and approximate sizes of the integrated health centres are as follows:

1) Etobicoke, Ontario Approximately 2,700 sq ft.

2) London, Ontario Approximately 3,100 sq ft.

3) Etobicoke, ON (site two) Approximately 2,900 sq ft.

“Dr. Aviv Tsimmerman and Dr. Jordan Rabinowitz are executing on our growth initiatives, they are achieving milestones, they are opening our healthcare centers.” said Steven McAuley, Chairman & CEO. “Our approach is based on patients and their needs, the delivery of care, an improved healthcare model, that provides advanced technology and access for an improved healthcare outcome.”

Each location is expected to host 4-6 physicians. Empower has already secured commitments from twelve (12) physicians to date, with numerous additional medical doctors and para-medical practitioners expressing interest to join the team.

“Having a strategic blend of health professionals allows us to provide an unparalleled integrative healthcare experience.” stated Dr. Jordan Rabinowitz, Chief Operating Officer. He further states, “This defines our path to assist millions of Canadians nationwide.”

HEALTH CARE SERVICES TO BE DELIVERED AND ANTICIPATED REVENUE MODEL

Empower will be opening primary care, plus para-medical healthcare services, with a target of four (4) to six (6) medical doctors and four (4) to six (6) paramedical practitioners per location.

Primary care services include:

  • Family physicians
  • Walk-in physicians
  • Tele-medicine and virtual care

Empower expects to generate $400,000 – $600,000 in annual revenue per MD, per location, which equates to a revenue range between $1,600,000 – $2,400,000 annually per location.

Paramedical services include:

  • Chiropractic
  • Physiotherapy
  • Registered Massage Therapy
  • Chiropody
  • Acupuncturists
  • Osteopaths
  • Nutritionists

Empower expects to generate $960,000 – $1,200,000 in annual revenue per location.

Together, when each location is fully operational, Empower expects to generate $2,560,000 – $3,600,000 in annual revenue per location.

ADDITIONAL HEALTH CARE SERVICES EXPECTED TO BE ADDED

Given the anticipated expansion and penetration of Empower Clinics into the Canadian market, the Company intends to continue adding valuable specialized medical services to strengthen the quality of healthcare at each location that can include:

  • Dermatology
  • Cardiology

Empower is currently in advanced discussions with potential partners in each of these specialty areas and believes they hold the potential to add significant value to the operations of each healthcare centre.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER:

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors:
Steven McAuley
CEO
[email protected]
604-789-2146

Investors:
Tamara Mason
Business Development & Communications
[email protected]
416-671-5617

Read more: https://agoracom.com/ir/EmpowerClinics/forums/discussion/topics/756054-empower-clinics-announces-locations-of-first-three-integrated-health-centres-in-ontario-each-location-anticipated-to-generate-approximately-3m/messages/2305329#message

POET Technologies $PTK.ca $POETF Targets New Markets for Co-Packaged Optics and Optical Sensing Applications with LightBar-C™ Product

Posted by AGORACOM-JC at 9:00 AM on Tuesday, February 23rd, 2021
  • Extended the Optical Interposer into new applications and markets with a fully-integrated, multiplexed light-source for optical computing chipsets and sensing applications, named “ LightBar-C™”.

TORONTO, Feb. 23, 2021 — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, announced that it has extended the Optical Interposer into new applications and markets with a fully-integrated, multiplexed light-source for optical computing chipsets and sensing applications, named “ LightBar-C™”.

The POET Optical Interposer platform has been extended and validated with the intrinsic features to support Conventional Band (“C-band”) and Long Band (“L-band”) lasers that produce light in a frequency range of 1530nm to 1625nm. POET has designed, developed and demonstrated cooled lasers for the Optical Interposer platform with up to 90mW of power operating at room temperature. In addition, the Company has designed and demonstrated a Dense Wavelength Division Multiplexer (“DWDM”) embedded in the Optical Interposer waveguide layer that allows channel spacings of 200GHz, providing the high density and broadband requirements needed for high-performance optical sensing and Co-Packaged Optics (CPO) applications, such as optical computing chipsets for Artificial Intelligence.

The Company’s first product to incorporate all of these features is the POET LightBar-C, which includes integrated spot-size converters that minimize coupling losses and increase power efficiency of components, such as multiplexers and detectors. The product provides low-loss fiber and free-space coupling, all specifically developed for highly integrated solutions within the C-band frequencies. The LightBar-C also utilizes a versatile and integrated laser source with multiple wavelengths (from 2 up to 8) multiplexed in the C-Band.

The optical bandwidth in the C-band is in the “eye-safe” region, which makes it ideal for free-space sensing applications. Consequently, C-band light solutions are expected to be foundational to the next generation of LiDAR solutions where high sensitivity, high power, reduced atmospheric influence and eye safety are presumed to be essential requirements.

Read More: https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/755882-poet-technologies-targets-new-markets-for-co-packaged-optics-and-optical-sensing-applications-with-lightbar-c-product/messages/2304892#message

POET Technologies $PTK.ca $POETF Provides Highlights and Results of Special Meeting

Posted by AGORACOM-JC at 10:35 AM on Monday, February 22nd, 2021
  • Announces the results of the Special Meeting (the “Meeting”) held virtually on Friday February 19, 2021.
  • Authorization from the Company’s shareholders to enable the Board of Directors, within its sole discretion, to consolidate the Company’s issued and outstanding common shares on the basis of one post-consolidation common share for a number of pre-consolidation common shares ranging between two (2) and fourteen (14) as outlined in the Company’s management information circular and voting material sent to the shareholders.

TORONTO, Feb. 22, 2021 – POET Technologies Inc. (“ POET ” or the “ Company ”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets announces the results of the Special Meeting (the “Meeting”) held virtually on Friday February 19, 2021.

The Company’s Chairman and Chief Executive Officer, Dr. Suresh Venkatesan, conducted the formal business of the Meeting, which focused solely on seeking authorization from the Company’s shareholders to enable the Board of Directors, within its sole discretion, to consolidate the Company’s issued and outstanding common shares on the basis of one post-consolidation common share for a number of pre-consolidation common shares ranging between two (2) and fourteen (14) as outlined in the Company’s management information circular and voting material sent to the shareholders.

Read More: https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/755798-poet-technologies-provides-highlights-and-results-of-special-meeting/messages/2304711#message

VIDEO – @goplantx $VEGA $PLTXF is the One-Stop-Shop for Everything Plant-Based $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 8:52 AM on Friday, February 19th, 2021
PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) aims to redefine the plant-based community through e-commerce, with a core objective of becoming the most trusted and convenient destination for people living plant-based lives. PlantX is a multifaceted marketplace providing consumers all things plant-based ranging from an efficient e-commerce experience, connecting consumers with interactive PlantX brick-and-mortar stores, and a PlantX home delivery system for products, meals, recipes, and more. Market Outlook With its comprehensive e-commerce platform, PlantX is strongly positioned for a prominent role in both the fast-growing plant-based food market, e-commerce and the online food delivery sectors. The global plant-based food market is expected to reach $74.2 billion by 2027, expanding at a CAGR of 11.9% . Similarly, the online food delivery market has steadily grown, especially during the current pandemic. This trend seems here to stay. In the United States alone, the sector is expected to report $28.5 billion by 2024, with companies such as UberEats experiencing 152% increases in food deliveries in the summer of 2020 . Complementary to these trends, and as a result of the COVID-19 pandemic, online sales and digitization have also both grown exponentially in 2020. Grocery shopping has seen a remarkable transition to e-commerce, with online grocery sales growing by 53% in 2020. Amid the pandemic-imposed physical interactions and related consumer behaviour change, large retailers have been compelled to meet this surge in e-commerce demand. For example, Whole Foods Markets has increased its online sales capacity by over 60% in 2020. The global meal kit delivery system is also becoming increasingly popular, and is expected to achieve $19.92 billion by 2027, expanding at a CAGR of 12.8%. PlantX aims to capitalize on this anticipated exponential market growth of the plant-based, e-commerce and home-delivery industries. Check out this video to find out more about investing in PlantX (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) VISIT OUR OFFICIAL WEBSITE https://plantx.ca/podcasts/​ https://plantx.ca/recipes/​ https://plantx.ca/shops/​ https://plantx.ca/product-category/pl…​ https://plantx.ca/plant-based-meal-de…​ Thanks for watching! We post new LIVE videos every week, so don’t forget to subscribe! LET’S STAY IN TOUCH https://www.tiktok.com/@goplantx​ https://www.facebook.com/goplantx​ https://www.instagram.com/goplantx/​ https://twitter.com/goplantx

Limitless Integrations to Utilize Draganfly $DFLY.ca $DFLYF Drones and AI Technology to Integrate Into its Mobile Onsite Detection Platform $FLT.ca $UAVS $ALPP

Posted by AGORACOM-JC at 9:23 AM on Wednesday, February 17th, 2021
  • Announced that it will provide drones and the Vital Intelligence detection AI technology for integration with the patent pending iDENT Mobile Onsight Detection Systems (“MODS”) offered by Limitless Integrations LLC
  • iDENT MODS platform is a self-contained turn-key entrance gateway designed to be rapidly deployed to locations requiring secure high throughput flow with instant secure access into any venue

Los Angeles, CA, Feb. 17, 2021 — Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly” or the “Company”), award-winning, industry-leading drone solutions, and systems developer, today announced that it will provide drones and the Vital Intelligence detection AI technology for integration with the patent pending iDENT Mobile Onsight Detection Systems (“MODS”) offered by Limitless Integrations LLC (“Limitless Integrations”).

The iDENT MODS platform is a self-contained turn-key entrance gateway designed to be rapidly deployed to locations requiring secure high throughput flow with instant secure access into any venue. The iDENT MODS can be utilized at festivals, worksites, military security perimeters, emergency response locations, and any scenario with high traffic volumes that require instant security.

With over 25 years of experience, Limitless Integrations offers its clients high-quality, reliable commercial and industrial physical security and health safety solutions. These solutions are specifically designed to meet the unique demands of venues and facilities of any size.

Draganfly will provide drones, tethered or otherwise for observation and threat detection for the perimeters where the Limitless iDENT MODS platforms are being utilized. The software on the drones can be used for general observation and security including possible weapons detection.

“Draganfly will provide the perfect partnership in enabling our MODS units to have a thorough screening process by way of their Vita Intelligence Technology delivered by drones,” said TJ Dooley CEO and co-founder of Limitless Integrations. “The technology solution that Draganfly offers will enhance the ability for our clients across a multitude of industries to provide a safe experience.”

“Draganfly is honored to have its technology and drones integrated into the incredible Limitless iDENT MODS platform. Helping provide the ability to securely and safely open venues or critical locations such as emergency response scenarios.”

Read More: https://agoracom.com/ir/Draganfly/forums/discussion/topics/755500-limitless-integrations-to-utilize-draganfly-drones-and-ai-technology-to-integrate-into-its-mobile-onsite-detection-platform/messages/2304012#message

@goplantx $VEGA $PLTXF Prices Offering and Files Amended and Restated Preliminary Short Form Prospectus $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 8:43 AM on Wednesday, February 17th, 2021
  • Filed an amended and restated short form preliminary short form prospectus in connection with the Offering.
  • The Offering will be at a price of $1.25 per unit of the Company for the issuance of a minimum of 8,000,000 Units to raise minimum total gross proceeds of $10,000,000 . 
  • The Offering, which will be conducted on a “best efforts” agency basis, is being led by Mackie Research Capital Corporation as lead agent and sole bookrunner.

VANCOUVER, BC , Feb. 17, 2021 – PlantX Life Inc. (the ” Company ” or ” PlantX “) (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF) is pleased to announce that it has priced its previously announced offering (the ” Offering “) in its February 16, 2021 news release and has today filed an amended and restated short form preliminary short form prospectus in connection with the Offering. The Offering will be at a price of $1.25 per unit of the Company (a ” Unit “) for the issuance of a minimum of 8,000,000 Units to raise minimum total gross proceeds of $10,000,000 .  The Offering, which will be conducted on a “best efforts” agency basis, is being led by Mackie Research Capital Corporation (the ” Agent “) as lead agent and sole bookrunner.

Each Unit will consist of one (1) common share of the Company (an ” Unit Share “, each such common share in the authorized capital structure of the Company, a ” Common Share “) and one (1) Common Share purchase warrant (a ” Warrant “). Each Warrant will be exercisable at a price of $1.45 and will entitle the holder to purchase one additional Common Share (a ” Warrant Share “) for a period of two (2) years from the closing of the Offering (the ” Closing “), provided that , if, at any time, the daily volume weighted average trading price (or closing price on trading days when there are no trades) of the Common Shares on the Canadian Securities Exchange (the ” CSE “) or, if the Common Shares are not listed on the CSE, then on such other recognized Canadian stock exchange on which the Common Shares are then listed, equals or exceeds $2.50 per Common Share over any ten (10) consecutive trading days, the Company shall be entitled, at its option, within ten (10) business days following such ten-day period, to accelerate the exercise period of the Warrants through the issuance of a press release (the ” Acceleration Notice “) specifying the new expiry date and, in such case, the Warrants will expire on the 30th day following the issuance of the Acceleration Notice. From and after the new expiry date specified in such Acceleration Notice, no Warrants may be issued or exercised, and all unexercised Warrants shall be void and of no effect following the new expiry date.

The net proceeds raised under the Offering will be used to fund expansion, to continue to develop a user app, to evaluate and pursue potential strategic acquisitions, and for working capital and general corporate purposes.

The closing of the Offering is currently expected to be on or about March 11, 2021 or such other date as agreed upon between the Company and the Agent, and is subject to certain conditions including, but not limited to, the execution of an agency agreement and the receipt of all necessary regulatory approvals including the approval of the CSE.

The Units are to be sold on a “best efforts” basis through the Agent in the provinces of British Columbia , Alberta and Ontario , and such other jurisdictions as the Agent and the Company may agree other than Quebec , and in the United States pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the ” U.S. Securities Act “) and all applicable U.S. state securities laws.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of these securities in the United States or to, or for the account or benefit of, U.S. persons. The securities described herein have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. “United States” and “U.S. person” are as defined in Regulation S under the U.S. Securities Act.

Read More: https://agoracom.com/ir/PlantX/forums/discussion/topics/755495-plantx-prices-offering-and-files-amended-and-restated-preliminary-short-form-prospectus/messages/2304002#message

POET Technologies $PTK.ca $POETF Reports on Financing Activities Ahead of Friday’s Special Meeting

Posted by AGORACOM-JC at 8:34 AM on Wednesday, February 17th, 2021

Clarifies Position on Implementation of Potential Share Consolidation

  • Added approximately C$24 million (US$18.8 million) to the Company’s cash balance as a result of the successful closing of a brokered private placement, warrants and stock options exercised since October 1, 2020.

TORONTO, Feb. 17, 2021 — POET Technologies Inc. (” POET ” or the ” Company “) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, has added approximately C$24 million (US$18.8 million) to the Company’s cash balance as a result of the successful closing of a brokered private placement, warrants and stock options exercised since October 1, 2020.

Exercise of Options and Warrants
The Company revealed that it had received approximately C$10 million from the exercise of options and warrants since October 1, 2020. Approximately C$2.7 million (US$2.1 million) came from the exercise of approximately 7 million options by former employees and directors at prices ranging from C$0.28 to $0.52. Approximately C$7.3 million (US$5.7 million) in proceeds came from the exercise of warrants from its public offering in November 2016 in which 34.8 million units, consisting of one common share and one common share purchase warrant with an exercise price of C$0.52 per share were placed. The majority of those warrants remained unexercised until recently. From November 2, 2016 through September 30, 2020 only 2.8 million had been exercised. Since the beginning of Q4 2020, warrant holders have exercised approximately 14 million of the 32 million warrants outstanding, with approximately 18 million still unexercised. The Company believes that the outstanding warrants are held mainly by Canadian investors. If fully exercised, the remaining warrants would result in proceeds of approximately C$9.4 million (US$7.3 million) being realized by the Company. If unexercised, the warrants will expire on November 2, 2021.

Warrants Associated with Convertible Debentures
The Company also issued warrants in connection with its private placement of 2-year Convertible Debentures (the “Debentures”) in the period April through September 2019. Holders of the Debentures have the option of redeeming for cash or converting into units consisting of one common share and one common share purchase warrant. The common share purchase warrant forming a part of such unit has an exercise price of C$0.50 per share. Approximately C$5 million (US$3.75 million) worth of the Debentures were issued representing approximately 12.5 million warrants that would be issuable upon conversion into units. Since being issued, the Company’s debt has been reduced by C$750,000 resulting in the issuance of 1.875 million shares and an equal number of warrants. Assuming all of the remaining Debentures are converted and the associated warrants exercised, the remainder of the Company’s debt would be extinguished, and it would issue an additional 10.6 million units. Upon exercise of the associated warrants, the Company would receive an additional C$5.3 million (US$4.1 million).   Depending on the purchase date, holders of the Debentures have between approximately 2 and 7 months remaining from the date of this press release to convert or redeem the Convertible Debentures.

Special Meeting
The Company clarified its intention for the Special Meeting to be held on Friday, February 19, 2021, which is being held for the sole purpose of seeking authorization from the Company’s shareholders to amend the articles of the Company to enable the Board of Directors to consolidate the total outstanding shares within a certain range. The proposed range, to be effected if, as and when the Board of Directors determines within its sole discretion to do so, is on the basis of one post-Consolidation Common Share for a number of pre-Consolidation Common Shares of between two and 14. Thomas Mika, Executive Vice President and Chief Financial Officer, made the following statement: “The purpose of seeking authorization from the shareholders for a consolidation is both to enable an additional listing on the NASDAQ Capital Market and to offer a combination of share price and total shares outstanding that meets or exceeds the minimum requirements of some of the larger institutional investors in the United States and Canada. The Board of Directors intends to consolidate shares only in connection with the additional listing and to do so only when the timing is appropriate, both internally and when market conditions allow. We cannot predict when conditions may be appropriate so we cannot say for certain when a consolidation may be implemented. Until then, we intend to continue to be listed on the TSX Venture Exchange (the “TSXV”) in Canada and on the OTCQX in the United States. So far, we are pleased to say that we have received overwhelming support for the resolution that will be voted on Friday.”

The authority of the Board to consolidate the shares in its sole discretion is conditional upon the prior approval of the Company’s shareholders and the TSXV. If approved by the Company’s shareholders and the TSXV, the consolidation would take place upon a decision by the Company’s Board of Directors within the proposed range agreed to by the shareholders following approval.

The Company will hold its Special Meeting virtually at 1:00pm EST on February 19, 2021 via the LUMI Meeting platform. A Management Information Circular in respect of the meeting has been mailed to shareholders and is available under the profile of the Company on SEDAR. Only registered shareholders, or shareholders with control numbers will be able to attend. No presentation by company management will be conducted and questions will be limited solely to the formal business of the meeting.

The Company also reported that its Total Shares Outstanding increased in recent weeks to 332,338,897 as a result of the successful closing of a brokered private placement, warrants and stock options exercised since October 1, 2020 which added approximately C$24 million (US$18.8 million) to the Company’s cash balance.

Read More: https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/755490-poet-technologies-reports-on-financing-activities-ahead-of-friday-s-special-meeting/messages/2303995#message

Valeo Pharma’s $VPH $VPHIF Hesperco Capsules at the Core of Montreal Heart Institute’s Hesperidin Coronavirus Clinical Trial $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 8:21 AM on Wednesday, February 17th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients
  • Hesperidin interferes / inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may disrupt the replication rate of the virus and enable infected patients to build natural immunity
  • Hesperidin’s safety profile and immune-modulatory activity make it a highly promising molecule to intervene at various stages of the COVID-19 infection process
  • Hesperco TM capsules contain 500mg of high purity concentrated hesperidin

MONTREAL , Feb. 17, 2021 – Valeo Pharma Inc . ( CSE:VPH) (OTCQB:VPHIF) (FSE:VP2 ) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company and its Hesperco™ development partner, Ingenew Pharma Inc. (“Ingenew”), are pleased to announce that Hesperco TM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”.

The MHI’s study will evaluate the effect of hesperidin on COVID-19 symptoms and its ability to reduce disease severity and the need for hospitalization in patients with COVID-19. The randomized, double-blind, placebo controlled study will enroll 216 confirmed COVID-19 symptomatic patients.

“The immune support properties of hesperidin, the medicinal ingredient contained in HESPERCO™ capsules, and its efficacy against other coronavirus strains are well documented in scientific literature. We are extremely proud to contribute in the fight against the COVID-19 virus with the prestigious MHI and our development partner Ingenew”, said Steve Saviuk , Valeo’s CEO. “Our involvement in this study aligns well with our vision to build a Canadian anchor pharmaceutical company and continued commitment to provide Canadian healthcare professionals and patients with innovative solutions to improve quality of life”.

Commenting on the  Montreal Heart Institute’s Hesperidin Coronovirus Study, Pierre Laurin , President and CEO of Ingenew, said: “We are pleased that MHI’s scientists  concur with our scientific findings.”

Read More: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/755488-valeo-pharma-s-hesperco-capsules-at-the-core-of-montreal-heart-institute-s-hesperidin-coronavirus-clinical-trial/messages/2303992#message